Superworth

Viridian Therapeutics price to book ratio VRDN

Market value divided by the book value of the company's net assets, since 2014.

Today, Oct 23, 2026
3.8×
10-year median
2.3×
Against its 10-year history
82nd
percentile: 0 is its lowest day, 100 its highest
10-year range
0.5× to 6.6×
Peer median
3.6×

Viridian Therapeutics' price to book ratio is 3.8× as of Oct 23, 2026.

That is above its ten-year median of 2.3×, higher than on 82% of days in the last ten years.

Over that time it ranged from 0.5× in Nov 2016 to 6.6× in Jul 2017.

The median for 10 large drugmakers of a similar size is 3.6×.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far3.8×1.9×6.3×
20256.0×1.5×6.1×
20242.2×1.3×4.1×
20234.0×1.6×4.2×
20222.9×1.4×4.8×
20212.1×0.9×4.3×
20203.1×0.7×3.7×
20190.7×0.6×2.1×
20181.4×1.2×5.8×
20176.0×0.8×6.6×
20160.8×0.4×1.5×
20150.6×0.5×3.0×
20141.1×1.1×2.3×

Against its peers

Companies in Drug Manufacturers - General nearest Viridian Therapeutics' size, closest first, today.

CompanyPrice to book ratio
VRDNViridian Therapeutics3.8×
NRIXNurix Therapeutics2.9×
PBHPrestige Consumer Healthcare1.2×
HRMYHarmony Biosciences2.1×
OGNOrganon3.6×
LQDALiquidia19.6×
ANIPANI Pharmaceuticals2.8×
ARQTArcutis Biotherapeutics17.8×
INDVIndivior Pharmaceuticalsn/m
PAHCPhibro Animal Health4.1×
ANABAnaptysbio138×
Peer median3.6×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Viridian Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.